Research Reinforces Blood Tests' Role in Diagnosing Alzheimer's Disease

Lund University

A new study from Lund University in Sweden shows that improved blood tests for the diagnosis of Alzheimer's disease can now be used with similar accuracy as the cerebrospinal fluid tests that have long been the standard in healthcare. The blood test has been approved for use in Europe, the US and Japan, among other places. The researchers hope that doctors will now gradually be able to use it more widely - and that, in many cases, patients will be able to avoid the more invasive cerebrospinal fluid test.

The study has now been published in the journal Nature Aging.

"These new findings are based on cutoff values that directly reflect clinical practice. The results show that this improved blood test, which has previously received FDA approval and CE marking for clinical use, is just as accurate as the established cerebrospinal fluid test - detecting Alzheimer's disease pathology with at least 90 percent accuracy

It is the first time this has been demonstrated," says Noëlle Warmenhoven, a doctoral student in the Clinical Memory Research Unit at Lund University.

The findings of this new study suggest that a blood test is just as accurate as cerebrospinal fluid testing.

PET imaging was used to verify that the blood tests are indeed accurate. It can be used to confirm the presence of Alzheimer's-related changes. One in five women and one in ten men develop Alzheimer's disease during their lifetime, but the tools available to the healthcare system for making a diagnosis have been limited. While specialised memory clinics have access to advanced techniques such as PET scans and cerebrospinal fluid tests, primary care is in great need of simpler and quicker diagnostic methods.

"Previous studies have used cerebrospinal fluid tests as a reference standard. Based on those articles, there are many clinicians that therefore believe the new blood tests are good, but probably not as good as the cerebrospinal fluid tests we already use. However, the findings of this new study contradict this and suggest that a blood test is just as accurate as cerebrospinal fluid testing," says Sebastian Palmqvist, associate professor and senior lecturer in neurology at Lund University and senior consultant at the Memory Clinic, Skåne University Hospital.

A key aspect of the study design is that the researchers have used regulatory approved, predefined cutoff values to determine whether the test result is positive, inconclusive or negative. Previous research has often evaluated the accuracy of blood tests using cutoff values developed specifically for the study in question. The problem is that such cutoff values are not the ones subsequently used in clinical practice.

"For example, you could establish a cutoff that perfectly distinguishes between people with and without Alzheimer's disease in Study A. But, if the same cutoff is then used in Study B, where the proportion of people without Alzheimer's is significantly higher, this could lead to many false positive results," says Noëlle Warmenhoven.

Predefined cutoffs, on the other hand, are designed to be broadly applicable in clinical practice, and are the cutoff values that physicians will actually use. The study has shown that the blood tests and cerebrospinal fluid tests perform equally well in an American research cohort, a Swedish memory clinic cohort and a Swedish primary care cohort. However, as Sebastian Palmqvist points out, at present the blood test is only recommended in memory clinics and other specialist healthcare units.

"However, work is currently underway to determine what implementation in primary care might look like. Further down the line, it may also become relevant to screen people with no memory problems at all, should drug treatments prove effective at that stage," says Sebastian Palmqvist.

About the blood test

The blood test shows a positive or negative result for Alzheimer's disease, but may also return an inconclusive result. Further investigation using a PET scanner or a cerebrospinal fluid test may then be required for a more reliable diagnosis. The patient must have cognitive symptoms.

The blood test measures the protein p-tau217, a biomarker specific to Alzheimer's disease. The US blood test, which has also been approved for use, measures p-tau217 in combination with the protein Aβ42 (amyloid-beta 42), a protein that begins to accumulate in the brain and form plaques in people with Alzheimer's disease. However, the Lund researchers have previously shown - and demonstrate once again in the latest study - that this combination does not necessarily perform better than measuring p-tau217 on its own.

On cutoff values and reference standards

Cutoff values are used to determine whether a test result is positive, negative or inconclusive. Previously, blood tests were only available in a research context, which meant that researchers had to calculate their own cutoff values - values that worked best for that particular study group and are not generally used in other studies. This means that test performance may vary between studies, depending on how well the cutoff has been chosen. Now that blood tests have been approved by the regulatory authorities, the manufacturers can provide cutoffs alongside the blood test to determine the test result.

To assess how effective a blood test is at detecting Alzheimer's, it is compared with a reference standard - an established method, such as a PET scan or cerebrospinal fluid testing. These are used as a reference to determine whether the changes associated with the disease are present in the brain. The aim is for the blood test to produce the same result as the reference standard as accurately as possible.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.